Stocks and Investing
Stocks and Investing
Thu, February 24, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Douglas Tsao Maintained (TBPH) at Strong Buy with Increased Target to $12 on, Feb 24th, 2022
Douglas Tsao of HC Wainwright & Co., Maintained "Theravance Biopharma, Inc." (TBPH) at Strong Buy with Increased Target from $8 to $12 on, Feb 24th, 2022.
Douglas has made no other calls on TBPH in the last 4 months.
There is 1 other peer that has a rating on TBPH. Out of the 1 peers that are also analyzing TBPH, all agrees with Douglas's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Increased Target to $12 on, Friday, November 5th, 2021
Contributing Sources